Brain Regions and Functional Neuronal Network Characteristics of Dexmedetomidine Analgesia
Status:
Not yet recruiting
Trial end date:
2022-09-20
Target enrollment:
Participant gender:
Summary
Background: Dexmedetomidine (DEX) is a highly selective 2-adrenergic receptor agonist with
significant analgesia affection. This study is planned to explore the brain regions and
functional neuronal network involved in promoting analgesia of Dexmedetomidine. Methods:
Select 12 patients with the proposed intraoperative MR-guided radiofrequency ablation of
epilepsy. The subjects were randomized into the Dexmedetomidine group (DEX group) (n=6) and
the Opioid group (OPI group) (n=6). DEX group: continuous intravenously administered 1.5 µg
kg-1 h-1 dexmedetomidine 15min before anesthesia induction, continuous infusion for 15min
after anesthesia induction, and then Intraoperative functional magnetic resonance imaging
scanning was started. OPI group: the equivalent administered speed 0.9% sodium chloride was
continuously pumped for 15min before anesthesia induction, then induce and intraoperative
fMRI scanning started after continuous 30min infusion. The intraoperative fMIR scan results
were compared and analyzed to find the unique analgesic brain regions of DEX, and the
differences of the functional neuronal network of analgesia effect between the two groups.